1. DISEASE CHARACTERISTICS 1.1 Name of the disease (synonyms) MUTYH-associated polyposis (MAP), Autosomal recessive colorectal adenomatous polyposis, Multiple colorectal adenomas, Multiple adenomatous polyps (MAP).
OMIM# of the disease

608456.
1.3 Name of the analysed genes or DNA/chromosome segments MUTYH (MYH, outdated name of the gene).
OMIM# of the gene(s)
604933.
Mutational spectrum
See Leiden Open Variation Database (LOVD) of the MUTYH gene (www.lovd.org/mutyh). 1 Broad, all types of point mutations (missense, splice site, and truncating mutations). [2] [3] [4] [5] Mutations were described in almost all exons (except exons 1 and 2). Gross genomic deletions or duplications seem to be very rare events, only one recurrent large deletion has been described so far. 6 In part ethnicity-specific mutational spectrum: two founder mutations -c.536A4G;p.Tyr179Cys (previously annotated as c.494A4G;p.Tyr165Cys or Y165C) in exon 7 and c.1187G4A; p.Gly396Asp (previously annotated as c.1145G4A;p.Gly382Asp or G382D) in exon 13 -dominate in individuals of North-Western European origin (together they account for around 80% of all reported mutant alleles) and are (almost) absent in Asia. Further ethnic-specific mutations include, for example, c.1437_1439delGGA;p.Glu480del (formerly c.1395_1397delGGA; p.Glu466del) (Southern Europe), c.312C4A;p.Tyr104X (formerly c.270C4A; p.Tyr90X) (Pakistan), and c.1438G4T;p.Glu480X (formerly c.1396G4T;p.Glu466X) (India).
Analytical methods
Direct sequencing of all 16 exons and flanking intronic sequences on genomic DNA (standard approach in routine diagnostics). Indirect screening of exons and flanking intronic sequences: dHPLC, CSGE, and melting curve analysis. Screening for founder mutations (useful only in patients of North-Western European origin): restriction digestion, ARMS, and pyrosequencing. Some procedures start with a screening for both founder mutations. If only one of them is detected, then the whole gene is searched for a second mutation. However, using this method a considerable proportion (up to 20%) of biallelic mutation carriers is missed. 2 Screening for large deletions and duplications with MLPA or other methods for gene dosage analysis can be considered, but is currently not generally recommended as routine diagnostic approach due to the very low frequency of this mutation type.
Analytical validation
As with other molecular genetic diagnostic tests, analytical results can be validated using standard procedures of internal and external quality assessment (EQA). These may include:
Internal validation through analysis of known mutations (positive controls). Direct sequencing of both DNA strands (bidirectional sequencing). Confirmation of mutation in an independent biological sample of the index case or an affected relative. In some cases (eg, single-exon deletions detected by MLPA), the results of semiquantitative methods should be confirmed by an independent technique (long-range PCR, RNA analysis, or different MLPA kit). External validation through exchange of DNA control samples with other diagnostic institutions and participation in EQA schemes (eg, www.emqn.org).
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence)
The frequency of MAP is around 15-20% in unselected APC mutation-negative patients with colorectal adenomatous polyposis of European origin. The prevalence is o1% in population-based CRC patients of European origin and up to 2% in familial or early onset CRC and Lynch syndrome/HNPCC cohorts. 7, 8 Assuming a CRC frequency of 5% in the general European population, the overall prevalence is assumed to be around 1:5000. Of note, up to one-third of biallelic MUTYH mutation carriers identified in population-based CRC studies developed CRC without a colorectal polyposis. 7 From the frequency of MUTYH heterozygotes in the general European population (1-1.5%) 3,9,10 the prevalence of biallelic carriers of MUTYH mutations (clinical plus subclinical biallelic carriers) can be derived as 1:40 000-1:20 000; however, the penetrance of biallelic MUTYH mutations is as yet unknown. 4 In Far Eastern Asian populations, no prevalent MUTYH mutations have been identified, and thus the heterozygote frequency is presumed to be lower compared with European populations.
If applicable, prevalence in the ethnic group of investigated person
The observed mutation patterns are not sufficient to derive ethnicityspecific prevalence rates. However, due to the presence of founder mutations among ethnic groups, differences in the frequency of MAP are likely to exist. The two hotspot mutations c.536A4G;p.Tyr179Cys and c.1187G4A;p.Gly396Asp observed in patients of European origin are almost absent in Far Eastern Asian populations.
Diagnostic setting
Yes No
Comment: Prenatal/preimplantation diagnosis is almost never requested. Since MAP is a relatively late-manifesting and treatable disease, it should be performed only exceptionally, in reasonable cases with clear indication and after extensive genetic counselling 
TEST CHARACTERISTICS
Negative predictive value: 
Clinical Specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
Almost 100% (except for variants of uncertain clinical significance).
Positive clinical predictive value (life-time risk to develop the disease if the test is positive)
Penetrance of CRC in proven biallelic mutation carriers, according to present knowledge, is up to 80%. Due to clinical variability, mildly affected persons may not be diagnosed or will be deceased for other reasons during presymptomatic (subclinical) stage of the disease. Relatives of MAP patients who are monoallelic mutation carriers (simple heterozygotes) may have a slightly increased CRC risk (odds ratio 1.5-2.1) in advanced age (450 years). 11 
Negative clinical predictive value (Probability not to develop the disease if the test is negative; although the population risk for CRC and adenomas remains)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been tested:
Almost 100% for sibs of index patient. The obligate heterozygous children of an index patient have a low risk (B0.5%) to carry a second mutation inherited from the other parent. Since the mutation detection rate in MUTYH is probably below 100%, the negative predictive value in this situation is slightly less than 100%, even if the whole gene is screened. Detection of a variant of uncertain clinical significance in the child of an affected person may not allow a secure decision on whether the test is 'negative' or not. De novo mutations have not been described so far.
pedigree pattern), and -particularly in attenuated courses of adenomatous polyposis -more and still unknown genes may be involved (locus heterogeneity), no exact figures can be given.
To test persons at risk without having identified the underlying germline mutations in a clearly affected index patient of the family is not a meaningful approach and should therefore be avoided, since persons at risk who are tested negative may still have a substantial risk and cannot be released from surveillance.
3. CLINICAL UTILITY 3.1 (Differential) diagnosis: The tested person is clinically affected (To be answered if in 1.10 'A' was marked)
MUTYH mutation analysis should be considered in patients with multiple (410) synchronous colorectal adenomas and rather young onset (o60 years of age) in the absence of a clear autosomal dominant inheritance pattern. Since hyperplastic polyps and sessile serrated adenomas are a common finding in MAP and the occurrence of CRC in the absence of colorectal polyps has been described, the clinical presentation might be misdiagnosed as hyperplastic polyposis or sporadic CRC in some patients. 7, 12 Phenotypic overlap with Lynch syndrome/ HNPCC has also been reported. 13 The frequency of biallelic MUTYH mutations is low (0.3-1.7%) in population-based and early-onset CRC cohorts and in patients with a low number of adenomas (o10) at any age, without an overt family history (and no carcinoma). For these cases, currently no general recommendations regarding MUTYH mutation analysis exist.
Can a diagnosis be made other than through a genetic test?
No & (continue with 3.1.4) Yes 2
In some rare cases, the condition can be assumed by family history (typical autosomal recessive inheritance pattern). However, the diagnosis must be confirmed by identification of biallelic MUTYH mutations. In the vast majority of patients differentiating MAP from APC-associated familial adenomatous polyposis (FAP) can be achieved by molecular genetic analysis only. 3, 4 3.1.2 Describe the burden of alternative diagnostic methods to the patient Family history: no strain.
3.1.3
How is the cost effectiveness of alternative diagnostic methods to be judged? Family history: very cost-effective. 
Will disease management be influenced by the result of a genetic test?
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe)
For many patients prove of diagnosis is a value in itselfirrespective of a medical benefit -because the disease and its cause can often clearly be named. When a genetic cause is verified, an assumption of 'own fault' as cause of disease (exogenous poisons, 'wrong conduct') often can be lapsed with relief. The main benefits of genetic diagnostics in MAP are the differentiation from FAP, a precise recurrence risk for close relatives, relief of non-carriers during predictive diagnostics, and a tailored surveillance programme including prophylactic surgery options.
